Can Heplisav-B be used to complete a vaccination series started with a 3-dose HepB vaccine: Engerix-B, Recombivax HB, or the discontinued product, PreHevbrio?

Yes. However, data are limited on the safety and immunogenicity effects when Heplisav-B is interchanged with HepB from other manufacturers. When feasible, the same manufacturer’s vaccines should be used to complete the series. However, vaccination should not be deferred when the manufacturer of the previously administered vaccine is unknown or when the vaccine from the same manufacturer is unavailable.

The 2-dose (4 weeks apart) complete HepB series only applies when both doses in the series consist of Heplisav-B. Series consisting of a combination of 1 dose of Heplisav-B and a vaccine from a different manufacturer should consist of 3 total vaccine doses and should adhere to the 3-dose schedule minimum intervals of 4 weeks between dose 1 and 2, 8 weeks between dose 2 and 3, and 16 weeks between dose 1 and 3. Doses administered at less than the minimum interval should be repeated. However, any series containing 2 doses of Heplisav-B administered at least 4 weeks apart is valid, even if the patient received an earlier dose from another manufacturer.